Control of intervertebral disc degeneration via matrix-mediated delivery of platelet-derived growth factors
通过基质介导的血小板衍生生长因子的传递来控制椎间盘退变
基本信息
- 批准号:10614929
- 负责人:
- 金额:$ 42.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:AftercareApoptosisApoptoticAutophagocytosisAutopsyBack PainBecaplerminBiocompatible MaterialsBiological AssayBiological Response Modifier TherapyBiomechanicsBlood PlateletsCellsChondrocytesClinicalCollagenComplementary DNACytokeratinDataData AnalysesDatabasesDiseaseDoseDrug Delivery SystemsEconomic BurdenEncapsulatedEngineeringExposure toFGF2 geneGAG GeneGene ExpressionGenerationsGenesGenetic TranscriptionGoalsGrowth FactorHeightHistologicHistologyHomeostasisHumanHydrogelsImageIn VitroInduction of ApoptosisInjectableInsulin-Like Growth Factor IIntervertebral disc structureLasersLightLinkLiteratureLow Back PainLoxP-flanked alleleMagnetic Resonance ImagingMeasuresMediatingMessenger RNAMicroscopyModalityModelingMolecularMusNeck PainOperative Surgical ProceduresOrthopedicsOryctolagus cuniculusOutcomeOutcome MeasurePathway AnalysisPlasmaPlatelet-Derived Growth FactorPlatelet-Derived Growth Factor alpha ReceptorPlatelet-Derived Growth Factor beta ReceptorPre-Clinical ModelPrevalenceProcessProductionPublic HealthPublishingPuncture procedureRUNX1 geneReportingRepressionResearchRoleSeminalSerumSignal TransductionSignaling MoleculeSocietiesStarvationSulfateSymptomsTailTestingTherapeuticTherapeutic EffectTissuesTransforming Growth Factor betaTransgenic OrganismsTreatment EfficacyValidationWorkcell growthdefined contributiondensitydisabilitygain of functionglobal healthhuman diseaseimprovedin vivoinhibitorintervertebral disk degenerationknock-downlaser capture microdissectionmechanical propertiesmonolayermouse modelnew therapeutic targetnovelnucleus pulposusoverexpressionplatelet-derived growth factor ABplatelet-derived growth factor BBpreclinical studypromoterresponsesecond harmonicsenescencesingle-cell RNA sequencingsmall hairpin RNAsocietal coststranscription factortranscriptomics
项目摘要
Summary
There is no successful biologic treatment for intervertebral disc degeneration (IDD). The goal of this proposal
is to utilize a hydrogel-based engineering approach to deliver PDGF to intervertebral disc (IVD) tissue and
establish PDGF as a potent inhibitor of IDD. We also aim to define the mechanisms underlying its effects on
normal and diseased nucleus pulposus (NP) and annulus fibrosus (AF) cells using human IVDs as well as
preclinical models of IDD.
The scientific premise for the proposed work is a rigorous body of published evidence demonstrating that PDGF-
BB, as well as PDGF-AB can stimulate disc cell growth and/or inhibit their programmed cell death in vitro. Our
compelling preliminary data in vivo point to an anti-apoptotic effect of PDGF-BB in a rabbit puncture model, which
led to restored disc height and enhanced mechanical properties of the treated discs compared to untreated
controls. It is based on these encouraging data and other molecular preliminary data demonstrating that these
anti-apoptotic effects may be mediated through the transcription factor Runx1, that we postulate the novel
hypothesis that sustained exposure of the NP and AF to PDGF will repress IDD progression through controlling
Runx1 activity.
To test this hypothesis, we will first compare the effects of PDGF-BB and PDGF-AB on normal versus diseased
human AF and NP cells cultured in high density. We will then determine the molecular mechanisms underlying
the anti-degenerative effects of PDGF on disc cells through transcriptomic and functional analyses involving
RUNX1 and other signaling molecules (Aim 1A). The validation of Runx1 function in PDGF-mediated effects will
also be examined in vivo using a new gain of function mouse model (Aim 1B). In the second Aim, we will
fabricate and validate the functionality of an injectable biomaterial capable of sustaining the exposure of disc
cells to PDGF-BB (Aim 2A). We will then establish therapeutic modalities for long-term inhibition of IDD in vivo
by PDGF-BB using a rabbit disc puncture model (Aim 2B). Our proposed work will provide seminal information
about the mechanisms underlying PDGF’s effects on the IVD and the role of Runx1 in IDD. The mechanistic
data will help identify new therapeutic targets to treat IDD.
摘要
目前还没有成功的生物治疗腰椎间盘退变(IDD)。这项提案的目标是
是利用一种基于水凝胶的工程方法将PDGF输送到椎间盘(IVD)组织和
使PDGF成为一种有效的IDD抑制剂。我们还旨在定义其影响的潜在机制
使用人类IVD的正常和病变髓核(NP)和纤维环(AF)细胞以及
IDD的临床前模型。
这项拟议工作的科学前提是一系列严格的已发表证据表明,PDGF-
BB和PDGF-AB在体外可刺激椎间盘细胞生长和/或抑制其程序性细胞死亡。我们的
令人信服的体内初步数据表明,PDGF-BB在兔穿刺模型中具有抗细胞凋亡的作用,该模型
从而恢复了盘的高度,并且与未处理的盘相比,提高了盘的机械性能
控制。它是基于这些令人鼓舞的数据和其他分子初步数据表明,这些
抗凋亡作用可能是通过转录因子RUNX1介导的,我们假设这是一种新的
假设NP和AF持续暴露于PDGF将通过控制抑制IDD进展
RUNX1活动。
为了验证这一假设,我们将首先比较PDGF-BB和PDGF-AB对正常和疾病的影响
高密度培养人房颤和神经节细胞。然后我们将确定潜在的分子机制
通过转录和功能分析研究PDGF对椎间盘细胞的抗退变作用
RUNX1和其他信号分子(目标1A)。RUNX1功能在PDGF介导的效应中的验证
也可以使用一种新的获得功能的小鼠模型(Aim 1B)在体内进行检查。在第二个目标中,我们将
制造和验证能够维持盘暴露的可注射生物材料的功能
细胞转化为PDGF-BB(Aim 2A)。然后,我们将在体内建立长期抑制IDD的治疗方法
PDGF-BB使用兔椎间盘穿刺术模型(目标2B)。我们提议的工作将提供开创性的信息
关于PDGF影响IVD的机制以及RUNX1在IDD中的作用。机械论
数据将有助于确定治疗IDD的新治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HICHAM M DRISSI其他文献
HICHAM M DRISSI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HICHAM M DRISSI', 18)}}的其他基金
Role of IL-17 receptor A in aging bone remodeling
IL-17受体A在衰老骨重塑中的作用
- 批准号:
10719356 - 财政年份:2023
- 资助金额:
$ 42.28万 - 项目类别:
Bone anabolic effects of osteoclast-produced phospho-Wnt5a
破骨细胞产生的磷酸化 Wnt5a 的骨合成代谢作用
- 批准号:
10929243 - 财政年份:2023
- 资助金额:
$ 42.28万 - 项目类别:
Control of intervertebral disc degeneration via matrix-mediated delivery of platelet-derived growth factors
通过基质介导的血小板衍生生长因子的传递来控制椎间盘退变
- 批准号:
10377961 - 财政年份:2021
- 资助金额:
$ 42.28万 - 项目类别:
CMA: Cartilage Repair Strategies to Alleviate Arthritic Pain (CaRe AP): Novel cell-based therapies to increase functional outcomes and alleviate pain in preclinical models of osteoarthritis
CMA:减轻关节炎疼痛的软骨修复策略 (CaRe AP):基于新型细胞的疗法,可提高骨关节炎临床前模型的功能结果并减轻疼痛
- 批准号:
10514601 - 财政年份:2020
- 资助金额:
$ 42.28万 - 项目类别:
CMA: Cartilage Repair Strategies to Alleviate Arthritic Pain (CaRe AP): Novel cell-based therapies to increase functional outcomes and alleviate pain in preclinical models of osteoarthritis
CMA:减轻关节炎疼痛的软骨修复策略 (CaRe AP):基于新型细胞的疗法,可提高骨关节炎临床前模型的功能结果并减轻疼痛
- 批准号:
10292959 - 财政年份:2020
- 资助金额:
$ 42.28万 - 项目类别:
Spatial and Temporal Role of the Runx3 Transcription Factor in Secondary Fracture Healing
Runx3 转录因子在二次骨折愈合中的时空作用
- 批准号:
10454763 - 财政年份:2020
- 资助金额:
$ 42.28万 - 项目类别:
Spatial and Temporal Role of the Runx3 Transcription Factor in Secondary Fracture Healing
Runx3 转录因子在二次骨折愈合中的时空作用
- 批准号:
10618866 - 财政年份:2020
- 资助金额:
$ 42.28万 - 项目类别:
CMA: Cartilage Repair Strategies to Alleviate Arthritic Pain (CaRe AP): Novel cell-based therapies to increase functional outcomes and alleviate pain in preclinical models of osteoarthritis
CMA:减轻关节炎疼痛的软骨修复策略 (CaRe AP):基于新型细胞的疗法,可提高骨关节炎临床前模型的功能结果并减轻疼痛
- 批准号:
10013786 - 财政年份:2020
- 资助金额:
$ 42.28万 - 项目类别:
Spatial and Temporal Role of the Runx3 Transcription Factor in Secondary Fracture Healing
Runx3 转录因子在二次骨折愈合中的时空作用
- 批准号:
9890844 - 财政年份:2020
- 资助金额:
$ 42.28万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Spatial Restriction of Apoptotic Machinery during Neuronal Apoptosis and Pruning
神经元凋亡和修剪过程中凋亡机制的空间限制
- 批准号:
10596657 - 财政年份:2021
- 资助金额:
$ 42.28万 - 项目类别:
Spatial Restriction of Apoptotic Machinery during Neuronal Apoptosis and Pruning
神经元凋亡和修剪过程中凋亡机制的空间限制
- 批准号:
10417219 - 财政年份:2021
- 资助金额:
$ 42.28万 - 项目类别:
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
- 批准号:
441952-2013 - 财政年份:2015
- 资助金额:
$ 42.28万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Understanding the activation of pro-apoptotic Bcl-2 family proteins for the development of modulators of apoptosis
了解促凋亡 Bcl-2 家族蛋白的激活以开发凋亡调节剂
- 批准号:
nhmrc : 1059331 - 财政年份:2014
- 资助金额:
$ 42.28万 - 项目类别:
Project Grants
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
- 批准号:
441952-2013 - 财政年份:2014
- 资助金额:
$ 42.28万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
- 批准号:
441952-2013 - 财政年份:2013
- 资助金额:
$ 42.28万 - 项目类别:
Postgraduate Scholarships - Doctoral
Apoptotic Osteocytes Promote Chondrocyte Apoptosis via Soluble Factors
凋亡骨细胞通过可溶性因子促进软骨细胞凋亡
- 批准号:
251802 - 财政年份:2012
- 资助金额:
$ 42.28万 - 项目类别:
Studentship Programs
Defining the mechanism(s) by which the cellular inhibitor of apoptosis protein 2 (cIAP2) contributes to early stage atherosclerosis development by directly promoting the participation of key apoptotic pathways within lesion-associated macrophages
确定凋亡蛋白细胞抑制剂 2 (cIAP2) 通过直接促进病变相关巨噬细胞内关键凋亡途径的参与来促进早期动脉粥样硬化发展的机制
- 批准号:
191299 - 财政年份:2009
- 资助金额:
$ 42.28万 - 项目类别:
Operating Grants
ATP release during apoptosis and its relevance to apoptotic cell clearance
凋亡过程中 ATP 释放及其与凋亡细胞清除的相关性
- 批准号:
8075522 - 财政年份:2009
- 资助金额:
$ 42.28万 - 项目类别:
ATP release during apoptosis and its relevance to apoptotic cell clearance
凋亡过程中 ATP 释放及其与凋亡细胞清除的相关性
- 批准号:
7676912 - 财政年份:2009
- 资助金额:
$ 42.28万 - 项目类别: